Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Accumulated Expenses (2016)

Historic Other Accumulated Expenses for Cartesian Therapeutics (RNAC) over the last 2 years, with Q2 2016 value amounting to $831000.0.

  • Cartesian Therapeutics' Other Accumulated Expenses changed N/A to $831000.0 in Q2 2016 from the same period last year, while for Jun 2016 it was $831000.0, marking a year-over-year change of. This contributed to the annual value of $223000.0 for FY2015, which is N/A changed from last year.
  • Per Cartesian Therapeutics' latest filing, its Other Accumulated Expenses stood at $831000.0 for Q2 2016.
  • Cartesian Therapeutics' 5-year Other Accumulated Expenses high stood at $831000.0 for Q2 2016, and its period low was $223000.0 during Q4 2015.